Top Markets
#1 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +585.95%
#2 Phala Phala +86.06%
#3 Bitway Bitway +35.59%
#4 龙虾 (Lobster) 龙虾 (Lobster) +27.08%
#5 Backpack Backpack +25.83%
#6 ARK ARK +24.61%
#7 Mubarak Mubarak +24.07%
#8 Aerodrome Finance Aerodrome Finance +23.48%
#9 APEX APEX +21.77%
#10 The Black Bull The Black Bull +20.57%
Coin of the day
Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain)
Beállítások
Nyelv
MAGYAR
Pénznem
USD
Téma
Ensysce Biosciences, Inc. Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc.

ENSC
Helyezés a részvények között #36735
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to... Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to developing novel prescription drugs for the treatment of severe pain in the United States, with a specific focus on preventing opioid addiction, misuse, abuse, and overdose. The company leverages two primary technological frameworks: the Trypsin Activated Abuse Protection (TAAP) platform, which creates opioid prodrugs designed to resist abuse, and the Multi-Pill Abuse Resistance (MPAR) platform, engineered to offer protection against overdose through its advanced opioid prodrug technology. Ensysce's pipeline features several key candidates, including PF614, an oxycodone prodrug developed using the TAAP platform, currently undergoing Phase II clinical trials for both acute and chronic pain management. Another product, PF614-MPAR, is a combination of PF614 and nafamostat, in Phase I clinical development to provide overdose protection against excessive oral consumption. Furthermore, the company is exploring an oral and inhaled formulation of nafamostat for potential use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. The company's development efforts also include PF329, an extended-release hydromorphone prodrug similar to PF614. In the area of ADHD treatment, Ensysce is advancing PF8001 and PF8026, which are extended-release and immediate-release amphetamine prodrugs, respectively, aimed at deterring medication abuse. Additionally, PF26810, an extended-release methadone prodrug, is in development for opioid use disorder. Ensysce Biosciences, Inc. operates from its headquarters in La Jolla, California.
Részvényárfolyam
$0.2483
Utolsó szinkronizálás: 2026-07-31
Piaci kapitalizáció
$2.30M
Változás (1 nap)
-3.39%
Változás (1 év)
-89.01%
Ország
US
Kereskedés Ensysce Biosciences, Inc. (ENSC)

Kategória

Healthcare
Bevétel a(z) Ensysce Biosciences, Inc. (ENSC) részvényhez
Bevétel ekkor: Jun 2026 TTM: $1.16M
Ensysce Biosciences, Inc. legfrissebb pénzügyi jelentései szerint a vállalat jelenlegi árbevétele (TTM) $1.16M. 2023 évben a vállalat $2.23M árbevételt ért el, amely csökkenés a 2022 évben elért $2.52M árbevételhez képest. Az árbevétel az a teljes összeg, amit a vállalat termékek vagy szolgáltatások eladásából generál. A nyereséggel ellentétben ebből nem vonódnak le költségek.
Ensysce Biosciences, Inc. bevételtörténete 2017 és 2026 között
Bevétel az év végén
Év Bevétel Változtassa meg
2026 (TTM) $1.16M -77.65%
2024 $5.21M 133.53%
2023 $2.23M -11.59%
2022 $2.52M -28.54%
2021 $3.53M -10.18%
2020 $3.93M 122.86%
2019 $1.76M 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
Hasonló cégek vagy versenytársak bevétele
Vállalat Bevétel Bevételkülönbség Ország
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B 1,084,168.43%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B 191,257.15%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B 517,052.77%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B 1,352,139.48%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH